Q2 2026 13F · SEC CIK 1674712

Vivo Capital, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $1.1B
Reported positions: 47
Top holdings a year, 3 yrs: +37.3%
Assets under management: $6.1B

Vivo Capital, LLC is a hedge fund that reported 47 positions worth $1.1B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Trevi Therapeutics Inc (TRVI, 8.7%), Praxis Precision Medicines I (PRAX, 8.3%), Erasca, Inc. (ERAS, 6.9%). A portfolio copying its top holdings returned 37.3% a year over the last 3 years, against 20.4% for the S&P 500.

Vivo Capital, LLC holdings all 47 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Vivo Capital, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
TRVITrevi Therapeutics Inc	8.7%	5.1%	5,094,668	+0.0%	$95.0M
PRAXPraxis Precision Medicines I	8.3%	9.1%	271,116	-20.0%	$90.8M
ERASErasca, Inc.	6.9%	16.3%	4,127,412	-66.0%	$75.6M
AVBPArrivent Biopharma Inc	5.3%	1.7%	1,682,097	+89.9%	$58.4M
ABVXAbivax SA	5.0%	2.2%	414,899	+73.2%	$55.3M
TNGXTango Therapeutics Inc	3.9%	3.7%	1,379,769	-36.0%	$43.1M
CRVSCorvus Pharmaceuticals Inc Com	3.8%	3.4%	2,805,816	+0.0%	$41.9M
10919W405Bright Minds Biosciences Inc	3.6%	3.4%	557,172	+0.0%	$39.1M
SVASinovac Biotech Ltd	3.5%	3.2%	5,903,000	+0.0%	$38.2M
TENXTenax Therapeutics Inc	3.3%	0.3%	2,500,000	+1100.0%	$36.4M
ACRSAclaris Therapeutics Inc	3.2%	2.1%	6,694,637	+0.4%	$35.4M
DYNDyne Therapeutics Inc	3.2%	2.3%	1,557,466	+0.0%	$34.6M
DNTHDianthus Therapeutics Inc	3.2%	2.5%	353,998	+0.0%	$34.5M
ANROAlto Neuroscience Inc	2.9%	1.9%	1,208,858	+16.7%	$31.9M
DBVTDbv Technologies S A	2.8%	4.6%	1,844,758	-30.8%	$30.3M
SABSSab Biotherapeutics Inc	2.6%	3.6%	7,299,909	-36.1%	$28.5M
MLTXMoonlake Immunotherapeutics	2.5%	1.6%	1,400,000	+40.0%	$27.3M
LBRXLB Pharmaceuticals, Inc.	2.4%	1.6%	800,000	+0.0%	$26.0M
NERVMinerva Neurosciences Inc	2.2%	2.2%	4,322,747	+0.0%	$24.0M
DSGNDesign Therapeutics, Inc.	2.1%	1.4%	1,612,903	+0.0%	$23.3M
ORICOric Pharmaceuticals Inc	1.8%	1.9%	1,848,786	+0.0%	$20.0M
CAMPCAMP4 Therapeutics Corporation	1.7%	1.6%	4,246,568	+0.0%	$18.6M
FTHFaeth Therapeutics Inc	1.6%	1.9%	722,020	+0.0%	$18.1M
ACHVAchieve Life Science Inc	1.6%	New	2,751,032	—	$18.0M
CMPXCompass Therapeutics Inc	1.6%	4.2%	7,757,060	-18.7%	$17.0M
ANTXAn2 Therapeutics Inc	1.4%	0.9%	3,153,640	+0.0%	$15.3M
EDITEditas Medicine Inc	1.1%	New	3,555,250	—	$11.5M
GERNGeron Corp	1.0%	1.1%	8,671,797	+0.0%	$11.1M
ODTXOdyssey Therapeutics, Inc.	1.0%	New	575,000	—	$10.8M
EPRXEupraxia Pharmaceuticals Inc	0.8%	0.8%	1,350,000	+0.0%	$8.9M
OKUROnkure Therapeutics Inc	0.8%	0.7%	1,927,710	+0.0%	$8.8M
OLMAOlema Pharmaceuticals Inc	0.8%	0.8%	671,843	+0.0%	$8.4M
MNPRMonopar Therapeutics Inc	0.8%	0.4%	90,500	+0.0%	$8.4M
AURAAura Biosciences Inc	0.8%	New	1,166,667	—	$8.3M
SRZNSurrozen Inc	0.6%	0.6%	260,000	+0.0%	$6.7M
ALXOAlx Oncology Hldgs Inc	0.6%	0.5%	3,184,713	+0.0%	$6.6M
MSLESatellos Bioscience Inc	0.6%	0.4%	813,666	+0.0%	$6.3M
AVTXAvalo Therapeutics Inc	0.5%	New	275,000	—	$5.1M
PEPGPepgen Inc	0.4%	0.3%	2,325,000	+0.0%	$4.2M
VALNValneva SE	0.4%	New	763,199	—	$4.0M
SERASera Prognostics Inc	0.3%	0.3%	1,650,440	+0.0%	$3.0M
UNCYUnicycive Therapeutics Inc	0.2%	1.0%	550,000	-69.3%	$2.6M
TILInstil Bio Inc	0.2%	0.2%	292,743	+0.0%	$2.3M
INMInMed Pharmaceuticals Inc	0.1%	New	798,377	—	$1.2M
BOLTBolt Biotherapeutics Inc	0.0%	0.0%	72,414	+0.0%	$279K
KTTAPasithea Therapeutics Corp	0.0%	0.1%	465,471	-77.8%	$240K
DTILPrecision Biosciences Inc	0.0%	0.0%	4,675	+0.0%	$37K

What Vivo Capital, LLC bought and sold in Q2 2026, against Q1 2026.

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +38.7% /yr; S&P 500 +20.2%
3 years: +37.3% /yr; S&P 500 +20.4%
5 years: +3.0% /yr; S&P 500 +11.2%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$1.1B	47
Q1 2026	$1.2B	46
Q4 2025	$1.5B	47
Q3 2025	$1.2B	47
Q2 2025	$977.1M	42
Q1 2025	$755.1M	40
Q4 2024	$892.6M	40
Q3 2024	$1.2B	43
Q2 2024	$1.1B	42
Q1 2024	$1.3B	42
Q4 2023	$1.2B	47
Q3 2023	$912.8M	53

Questions about Vivo Capital, LLC's portfolio

What stocks does Vivo Capital, LLC own?

Vivo Capital, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 47 positions worth $1.1B. The largest are Trevi Therapeutics Inc (TRVI) at 8.7%, Praxis Precision Medicines I (PRAX) at 8.3%, Erasca, Inc. (ERAS) at 6.9%, Arrivent Biopharma Inc (AVBP) at 5.3% and Abivax SA (ABVX) at 5.0%.

What did Vivo Capital, LLC buy last quarter?

In Q2 2026, Vivo Capital, LLC added a new position in Achieve Life Science Inc (ACHV), a new position in Editas Medicine Inc (EDIT), a new position in Odyssey Therapeutics, Inc. (ODTX), a new position in Aura Biosciences Inc (AURA), a new position in Avalo Therapeutics Inc (AVTX), Tenax Therapeutics Inc (TENX) (+1100.0% shares), Arrivent Biopharma Inc (AVBP) (+89.9% shares) and Abivax SA (ABVX) (+73.2% shares), compared with its Q1 2026 filing.

What did Vivo Capital, LLC sell last quarter?

In Q2 2026, Vivo Capital, LLC sold all of Terns Pharmaceuticals Inc (TERN), sold all of Veradermics Inc (MANE), sold all of Cogent Biosciences Inc (COGT), sold all of Soleno Therapeutics Inc (SLNO), sold all of Viridian Therapeutics Inc (VRDN), Pasithea Therapeutics Corp (KTTA) (-77.8% shares), Unicycive Therapeutics Inc (UNCY) (-69.3% shares) and Erasca, Inc. (ERAS) (-66.0% shares), compared with its Q1 2026 filing.

How has Vivo Capital, LLC's portfolio performed?

A portfolio copying Vivo Capital, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +37.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +38.7% against +20.2%. Over 5 years: +3.0% a year against +11.2%.

When is Vivo Capital, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Vivo Capital, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Vivo Capital, LLC manage?

Vivo Capital, LLC reported $6.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.1B.